Clinical Trials Sponsored by Anthem, Inc

Total 35566 results

Anthos Therapeutics, Inc.

Recruiting

Study to evaLuate the effIcacy and Safety of abeLacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral antiCoagulation (LILAC-TIMI 76) (LILAC-TIMI 76)

Atrial Fibrillation (AF)

United States, Canada, Israel, Japan, China, Brazil, Chile, United Kingdom, Bulgaria, Germany, Hungary, Italy, Poland, Romania, Spain, Czechia, Latvia, Mexico
Anthos Therapeutics, Inc.
Itreas

Recruiting

A Study Comparing Abelacimab to Apixaban in the Treatment of Cancer-associated VTE (ASTER)

Venous Thromboembolism | Pulmonary Embolism | Deep Venous Thrombosis

Austria, United States, Taiwan, Australia, Spain, Japan, Canada, Ireland, Italy, Korea, Republic of, France, Switzerland, Hungary, Netherlands, Latvia, Germany, Norway, Sweden, Czechia, United Kingdom
Anthos Therapeutics, Inc.
Covance

Completed

A Dose-range Finding Study of MAA868 in Patients With Atrial Fibrillation

Atrial Fibrillation

United States
Anthem, Inc
University of California, Irvine; HealthCore, Inc.; Apple Inc.; CareEvolution, LLC

Completed

Asthma Digital Study (ADS)

Asthma

United States
Anthos Therapeutics, Inc.
Itreas

Recruiting

A Study Comparing Abelacimab to Dalteparin in the Treatment of Gastrointestinal/Genitourinary Cancer and Associated VTE (MAGNOLIA)

Venous Thromboembolism | Pulmonary Embolism | Deep Venous Thrombosis

Austria, United States, Taiwan, Australia, Spain, Korea, Republic of, Italy, Hungary, France, Netherlands, Canada, Latvia, Germany, United Kingdom, Norway, Sweden, Ireland, Czechia, Switzerland
Anthos Therapeutics, Inc.
CYTE Global

Recruiting

Study in Atrial Fibrillation (AF) Patients at High Risk of Stroke (GARDENIA)

Atrial Fibrillation

United States, Czechia, Poland, Spain, Germany, Canada, Hungary, United Kingdom, Argentina, Italy, Brazil, Mexico
Anthea Hospital Bari

Not yet recruiting

Electric Polarization of Red Blood Cells : A Cohort Study to Assess the Erythrocytes Membrane Integrity Through Charge Conservation, Following Cardiac Surgery. (Polaris)

Inflammatory Response | Hemolysis | Cardiovascular Disorder | Red Blood Cell Disorder | Erythrocyte Destruction

Italy
Anthea Hospital Bari

Completed

Jafron Haemoadsorption During Cardiopulmonary Bypass (JAFRONCPB)

Cytokine Release Syndrome

Italy
University of Florida
Alchem Laboratories, Inc

Completed

Topical NanoDox® for Atopic Dermatitis

Dermatitis, Atopic

United States
Beijing Anzhen Hospital
Beckman Coulter, Inc.

Unknown

Study on High-sensitivity Troponin 0h/1h for Rapid Diagnosis of Non-ST-segment Elevation Myocardial Infarction in the Chinese Population

Non-ST-segment Elevation Myocardial Infarction

China
Midwest Evaluation & Research
Anthem Strong Families

Recruiting

TYRO Champion Dads Project Study

Fathers

United States
Midwest Evaluation & Research
Anthem Strong Families

Recruiting

Family Champions Project

Mothers | Fathers

United States
Anchen Pharmaceuticals, Inc
Novum Pharmaceutical Research Services

Completed

Evaluation of Clinical Equivalence Between Two Lubiprostone Products

Chronic Idiopathic Constipation

United States
Anchen Pharmaceuticals, Inc
Novum Pharmaceutical Research Services

Completed

Evaluation of Clinical Endpoints of Two Diclofenac Sodium Gel 1%

Osteo Arthritis of the Knee

United States
Anthera Pharmaceuticals

Completed

SOLUTION: Study of Oral Liprotamase Unit-Matched Therapy Of Non-Porcine Origin in Patients With Cystic Fibrosis

Cystic Fibrosis | Exocrine Pancreatic Insufficiency

United States, Hungary, Israel, Poland, Spain, Canada, Czechia
Anthera Pharmaceuticals

Completed

SIMPLICITY: Studying Impacts on Malabsorption With Liprotamase in Cystic Fibrosis (SIMPLICITY)

Cystic Fibrosis | Exocrine Pancreatic Insufficiency

United States
Anthera Pharmaceuticals

Withdrawn

CHABLIS-SC2: A Study of the Efficacy and Safety of Subcutaneous Blisibimod in Subjects With Systemic Lupus Erythematosus With or Without Nephritis

Systemic Lupus Erythematosus
Anthera Pharmaceuticals

Withdrawn

BIANCA-SC: A Study of the Efficacy, Safety, and Tolerability of Blisibimod in Addition to Methotrexate During Induction of Remission in Subjects With ANCA-Associated Small Vessel Vasculitis (BIANCA-SC)

Microscopic Polyangiitis | Granulomatosis With Polyangiitis
Anthera Pharmaceuticals

Withdrawn

BRILLIANT-SC: A Study of the Efficacy and Safety of Blisibimod Administration in Subjects With IgA Nephropathy

IgA Nephropathy
Anthera Pharmaceuticals

Terminated

Phase III ALTU-135 CP Safety Trial (DIGEST CP)

Exocrine Pancreatic Insufficiency

United States
Anthera Pharmaceuticals

Completed

Liprotamase Efficacy Trial in Patients With Cystic Fibrosis-Related Exocrine Pancreatic Insufficiency (DIGEST)

Cystic Fibrosis | Exocrine Pancreatic Insufficiency

United States
Anthera Pharmaceuticals

Completed

PEARL-SC Trial: A Study of the Efficacy, Safety, and Tolerability of A 623 Administration in Subjects With Systemic Lupus Erythematosus (PEARL-SC)

Systemic Lupus Erythematosus

United States, Argentina, Brazil, Chile, Colombia, Hong Kong, India, Mexico, Peru, Philippines, Taiwan
Anthera Pharmaceuticals

Completed

PLASMA 2 Trial: Examination of Once Daily (QD) Dosing of A-002 In Subjects With Stable Coronary Artery Disease (PLASMA 2)

Coronary Artery Disease

United States
Anthera Pharmaceuticals

Completed

BRIGHT-SC: Blisibimod Response in IgA Nephropathy Following At-Home Treatment by Subcutaneous Administration

IgA Nephropathy

Czechia, Germany, Hong Kong, Korea, Republic of, Malaysia, Philippines, Singapore, Taiwan, Thailand, United Kingdom
Anthera Pharmaceuticals

Completed

FRANCIS-ACS Trial: A Study of the Safety and Efficacy of A 002 in Subjects With Acute Coronary Syndromes (FRANCIS-ACS)

Acute Coronary Syndrome

Russian Federation, Georgia, Ukraine
Anthera Pharmaceuticals

Terminated

A Study of Varespladib Infusion in Subjects With Sickle Cell Disease. (IMPACTS-2)

Sickle Cell Disease | Vaso-occlusive Crisis

United States
Anthera Pharmaceuticals

Completed

A Trial for Subjects With Systemic Lupus Erythematosus Who Have Completed Protocol AN-SLE3321

Systemic Lupus Erythematosus

United States, Argentina, Brazil, Chile, Colombia, Hong Kong, India, Mexico, Peru, Philippines, Taiwan
Anthera Pharmaceuticals

Terminated

VISTA-16 Trial: Evaluation of Safety and Efficacy of Short-term A-002 Treatment in Subjects With Acute Coronary Syndrome (VISTA-16)

Acute Coronary Syndrome

United States, Australia, Canada, Czech Republic, Georgia, Germany, Hungary, India, Italy, Korea, Republic of, Lebanon, Netherlands, New Zealand, Poland, Russian Federation, Spain, Ukraine
Anthera Pharmaceuticals

Terminated

A Study of the Pharmacokinetics and Safety of Varespladib in Subjects With Normal or Impaired Renal Function

Renal Impairment

United States
Anthera Pharmaceuticals

Completed

Study to Assess the Metabolism and Elimination of [14C]-Labeled Varespladib Methyl in Healthy Male Subjects

Healthy Volunteers

United States
Anthera Pharmaceuticals

Completed

EASY: Extended Access to Sollpura Over Years

Cystic Fibrosis | Exocrine Pancreatic Insufficiency

United States, Hungary, Israel, Poland, Spain, Czechia
Anthera Pharmaceuticals

Unknown

RESULT: Reliable, Emergent Solution Using Liprotamase Treatment

Cystic Fibrosis | Exocrine Pancreatic Insufficiency

United States, Hungary, Israel, Lithuania, Poland, Spain, United Kingdom
Anthera Pharmaceuticals

Terminated

CHABLIS7.5: A Study of the Efficacy and Safety of Subcutaneous Blisibimod in Subjects With Systemic Lupus Erythematosus With or Without Nephritis

Systemic Lupus Erythematosus

Georgia
Anthera Pharmaceuticals

Completed

CHABLIS-SC1: A Study of the Efficacy and Safety of Subcutaneous Blisibimod in Subjects With Systemic Lupus Erythematosus (CHABLIS-SC1)

Systemic Lupus Erythematosus

Georgia, Belarus, Brazil, Colombia, Guatemala, Hong Kong, India, Korea, Republic of, Malaysia, Mexico, Philippines, Russian Federation, Singapore, Sri Lanka, Taiwan, Thailand
Anthera Pharmaceuticals

Withdrawn

MONICA-SC: A Study to Evaluate the Efficacy, Safety and Tolerability of Blisibimod (A-623) Administration in Subjects With ITP

Idiopathic Thrombocytopenic Purpura | Immune Thrombocytopenic Purpura
Anthera Pharmaceuticals

Completed

Open-Label Phase III Long-Term Safety Trial of Liprotamase (DIGEST)

Cystic Fibrosis | Exocrine Pancreatic Insufficiency

United States
Anthera Pharmaceuticals

Completed

IMPACTS Trial: Investigation of the Modulation of Phospholipase in Acute Chest Syndrome

Sickle Cell Disease | Acute Chest Syndrome | Vaso-occlusive Crisis

United States
Anthera Pharmaceuticals

Completed

PLASMA Trial: A Dose-Response Study of A-002 In Subjects With Stable Coronary Artery Disease (PLASMA)

Coronary Artery Disease (CAD)

United States, Ukraine
Beijing Anzhen Hospital

Recruiting

PrevaLence of Albuminuria in Patients With CARdiovascular Disease and Type 2 Diabetes Mellitus in China: a National Cross-sectional Study (PLACARD)

Cardiovascular Disease | Type 2 Diabetes Mellitus

China
Beijing Anzhen Hospital

Not yet recruiting

Henagliflozin in Patients With Atrial Fibrillation (HENA-AF)

Atrial Fibrillation

China
Beijing Anzhen Hospital

Not yet recruiting

Effects of Different Revascularization StrateGies in Complex Coronary Artery DiseasE (EDGE)

Coronary Artery Disease
Beijing Anzhen Hospital

Recruiting

SAfety and EFficacy of Bridging Antithrombotic Therapy During Elective Non-cardiac Surgery (SAFE)

Coronary Artery Disease

China
Beijing Anzhen Hospital

Completed

CompArison of PCI in NaTive Arteries Versus ByPAss Grafts In PatieNts With Prior CABG (CAPTAIN)

Coronary Artery Disease

China
Beijing Anzhen Hospital

Completed

OSA-ACS Project: Association of OSA and CPAP Therapy With Outcomes in ACS Patients

Acute Coronary Syndrome | Obstructive Sleep Apnea of Adult

China
Beijing Anzhen Hospital

Unknown

The Influence of Gene Polymorphism on Clinical Outcomes in Patients Undergoing PCI

Antiplatelet Therapy | CYP2C19 Polymorphism

China
Beijing Anzhen Hospital

Unknown

LOwer Maintenance Dose TICagrelor in Acute Coronary Syndrome Patients Undergoing Percutaneous Coronary Intervention (LOTIC)

Coronary Artery Disease | Percutaneous Coronary Intervention | Antiplatelet Therapy

China
Beijing Anzhen Hospital

Unknown

Hemoperfusion in Extracorporeal Membrane Oxygenation (ECMO) Patients

Cardiogenic Shock

China
Beijing Anzhen Hospital

Unknown

Improvement on Diagnosis of Fetal Congenital Heart Disease Based on Multi-center Collaboration in China

Congenital Heart Disease | Diagnosis | Echocardiography

China
Beijing Anzhen Hospital

Unknown

Effect of Dexmedetomidine on Stress Study of Pituitrin in Laparoscopic Hysteromyoma Surgery

Hysteromyoma
Beijing Anzhen Hospital

Unknown

Small Doses of Pituitrin Versus Norepinephrine for the Management of Vasoplegic Syndrome in Patients After Cardiac Surgery

Postoperative Vasoplegic Syndrome

China

Clinical Trials Sponsored by Anthem, Inc

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in United Arab Emirates

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations